Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | WEHI-539 |
Trade Name | |
Synonyms | |
Drug Descriptions |
WEHI-539 is a selective inhibitor of BCL-XL that stimulates apoptotic responses in cells, resulting in killing of tumor cells (PMID: 23603658, PMID: 32752193). |
DrugClasses | BCL-XL inhibitor 14 |
CAS Registry Number | 1431866-33-9 |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
A-1210477 + Lapatinib + WEHI-539 | A-1210477 Lapatinib WEHI-539 | 0 | 0 |
A-1210477 + WEHI-539 | A-1210477 WEHI-539 | 1 | 0 |
Alpelisib + WEHI-539 | Alpelisib WEHI-539 | 1 | 0 |
Buparlisib + WEHI-539 | Buparlisib WEHI-539 | 1 | 0 |
Dactolisib + WEHI-539 | Dactolisib WEHI-539 | 5 | 0 |
G-TPP + WEHI-539 | G-TPP WEHI-539 | 0 | 0 |
Sapanisertib + WEHI-539 | Sapanisertib WEHI-539 | 1 | 0 |
Sirolimus + WEHI-539 | Sirolimus WEHI-539 | 0 | 0 |
Torin 1 + WEHI-539 | Torin 1 WEHI-539 | 1 | 0 |
Vistusertib + WEHI-539 | Vistusertib WEHI-539 | 1 | 0 |
VX-11e + WEHI-539 | VX-11e WEHI-539 | 1 | 0 |
WEHI-539 | WEHI-539 | 0 | 0 |